Stay updated with breaking news from Helena levander. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
At the annual general meeting today of Stendörren Fastigheter AB , the shareholders resolved mainly on the following points in accordance with the presented. | May 23, 2023 ....
At the annual general meeting of Rejlers AB , reg. no 556349-8426, on 20 April 2023 the AGM adopted, inter alia, the following resolutions. For more detailed information regarding the contents of. | April 20, 2023 ....
Medical device company Occlutech Holding AG, one of the world?s leading providers of minimally invasive structural heart disease devices, announces the election of four new members to the board Occlutech Holding AG ( Occlutech ) today announces that Marianne Dicander Alexandersson, Mette-Marie Harild, Helena Levander, and Michel Lussier have been elected as members of the Board of Directors of Occlutech. Marianne Dicander Alexandersson will be nominated as the Chair of the Board of Directors of Occlutech at the Annual General Meeting on 18 June 2021. We are delighted to welcome Marianne, Mette-Marie, Helena, and Michel to Occlutech s board. Their collective management and industry experience will be of utmost value to Occlutech as we continue on our exciting journey to drive the development of world leading products, grow revenue and expand further geographically, said Sabine Bois, Chief Executive Officer of Occlutech. ....
Resolutions at the Annual General Meeting in Medivir on 5 May 2021 News provided by Share this article HUDDINGE, Sweden, May 5, 2021 /PRNewswire/ Approval of profit and loss accounts and balance sheets, and discharge from liability of the board members and the managing director The annual general meeting in Medivir Aktiebolag (publ) on 5 May 2021 resolved to approve the profit and loss accounts and balance sheets for the financial year 2020. The persons who had been board members and managing directors were discharged from liability with respect to their respective management of the company for the financial year 2020. Appropriation of the company s profit or loss ....
Financing secured to bring the MIV-818 study into the next phase January – March Net turnover amounted to SEK 9.9 (7.3) million. The loss before interest, tax, depreciation and amortization (EBITDA) amounted to SEK -7.2 (-20.7) million. Basic and diluted earnings per share amounted to SEK -0.18 (-0.96) and SEK -0.18 (-0.96) respectively. Cash flow from operating activities amounted to SEK -1.5 (-16.6) million. Liquid assets and short-term investments at the end of the period amounted to SEK 269.3 (116.6) million. Significant events during the quarter In January the company signed an exclusive license agreement with IGM Biosciences, Inc. for birinapant. Medivir received a payment of USD 1 million after signing, which is to be followed by an additional USD 1.5 million when IGM includes birinapant in phase I clinical trials. In addition, the agreement entitles Medivir to milestone payments and royalties. ....